Last updated: 2026-11-14 22:13:40. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Delcath Systems Inc. (DCTH) operates in the SURGICAL & MEDICAL INSTRUMENTS & APPARATUS sector and is listed on NASDAQ. The stock is currently priced at $20.52, with a market capitalization of $743.77M and a P/E ratio of 107.44. Over the past 52 weeks, its price has ranged from $8.12 to $22.51. This page covers its latest market performance, valuation, price trends and company information.
$743.77M | |
$21.44 | |
$21.94 | |
$20.21 | |
$21.38 | |
593.47K | |
485.89K | |
107.44 | |
$22.51 | |
$8.12 | |
-- | |
-- |
Delcath Systems Inc. (DCTH) last closed at $20.52 as of 2026-11-14 00:57:00, down 4.05% ($0.86) from the previous close of $21.38.
During the latest regular trading session, DCTH traded between $20.21 and $21.94, with a volume of 593.47K shares. The closing price was near the lower end and near the upper end of its 52-week range.
Over the past seven days, Delcath Systems Inc. (DCTH) moved from $14.49 to $20.52, representing a gain of 41.61% ($6.03).
The stock traded between $14.24 and $22.51 during the period. The latest price is near the upper end of the 7-day range, indicating strong upward.
The average daily volume was 1.54 million shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 86.2%
DCTH is currently trading at $20.52, placing it 86.2% of the way from its 52-week low of $8.12 to its 52-week high of $22.51. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Delcath Systems Inc is an oncology company. The company is focused on the treatment of primary and metastatic liver cancers. The firm's product include Melphalan Hydrochloride, Hepzato for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.
| Industry | SURGICAL & MEDICAL INSTRUMENTS & APPARATUS |
| Employees | 156 |
| Exchange | NASDAQ |
| Company Website |
Latest news related to Delcath Systems Inc. and DCTH stock.
Delcath Systems (DCTH) has been identified as a strong momentum stock with a Zacks Rank #1 (Strong Buy) rating and Momentum Style Score of A. The stock has shown impressive performance with a 47.89% monthly gain and 153.43% yearly gain, significantly outperforming the S&P 500. Recent earnings estimate revisions have moved upward, with consensus estimates improving from -$0.17 to $0.13 in the past 60 days.
Delcath Systems (DCTH) has a mean analyst price target of $27.8, suggesting 27.7% upside potential from its current $21.77 price. The stock has gained 47.9% over the past four weeks. Analysts have revised earnings estimates higher, and DCTH holds a Zacks Rank #1 (Strong Buy) rating. However, the article cautions that price targets can be misleading and should not be the sole basis for investment decisions.
BTIG analyst Marie Thibault reiterates Delcath Systems (NASDAQ:DCTH) with a Buy and maintains $25 price target.
Eligible investors can buy real shares of Delcath Systems Inc. (DCTH) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
See US stocks with the highest market capitalization
Discover today's most actively traded US stocks
Browse today's leading gainers in the US stock market
Explore the cryptocurrencies with the highest market capitalization
Stock prices and market data on this page, including price changes and market status, are provided by Massive and other third-party news and data platforms. Market data may be delayed and may differ from prices on other platforms or the prices at which trades are executed on MEXC. MEXC does not guarantee the accuracy, completeness, or timeliness of third-party data. MEXC offers trading products related to DCTH, including Stocks, Tokenized Stocks, and Stock Futures.
The stock price information displayed on this page is provided for reference purposes only and may be delayed or differ from real-time market data. Prices, charts, and related metrics do not constitute investment advice and should not be relied upon for trading or investment decisions. MEXC is not responsible for any losses incurred based on the stock price information provided on this page. Please refer to official market sources or consult licensed financial professionals before making any investment decisions.
Estimate the value between DCTH shares and USD.
DCTH Shares to USD
1.00 DCTH shares = 20.52 USD
Calculations are estimates based on the latest available price and are for reference only.
